KR950002785A - 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 - Google Patents

골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 Download PDF

Info

Publication number
KR950002785A
KR950002785A KR1019940017456A KR19940017456A KR950002785A KR 950002785 A KR950002785 A KR 950002785A KR 1019940017456 A KR1019940017456 A KR 1019940017456A KR 19940017456 A KR19940017456 A KR 19940017456A KR 950002785 A KR950002785 A KR 950002785A
Authority
KR
South Korea
Prior art keywords
parathyroid hormone
raloxyphene
bone mass
raloxifene
increase bone
Prior art date
Application number
KR1019940017456A
Other languages
English (en)
Other versions
KR100306852B1 (ko
Inventor
메리 혹크 쟈넷
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950002785A publication Critical patent/KR950002785A/ko
Application granted granted Critical
Publication of KR100306852B1 publication Critical patent/KR100306852B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 PTH와 랄옥시펜을 투여함으로써 환자의 골량을 증가시키는 방법에 관한 것이다. 본 발명의 다른 요지는 PTH와 랄옥시펜을 투여함으로써 환자의 골 손실을 치료하는 방법이다. 본 발명은 또한 환자의 골량을 증가시키기 위한 PTH와 랄옥시펜의 조성물을 제공한다. 본 발명의 다른 요지는 환자의 골 손실을 치료하기 위한 PTH와 랄옥시펜의 조성물이다.

Description

골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 인간의 골량을 증가시키거나 또는 골 손실을 치료하기 위하여 함께 사용하기 위한 부갑상선 호르몬 및 랄옥시펜.
  2. 제1항에 있어서, 부갑상선 호르몬과 랄옥시펜을 동시에 투여하는 화합물.
  3. 제1항에 있어서, 부갑상선 호르몬과 랄옥시펜을 연속적으로 투여하는 화합물.
  4. 1개 이상의 약학적으로 허용가능한 부형제와 함께 부갑상선 호르몬 및 랄옥시펜을 포함하는 약학적 조성물.
  5. 제4항에 있어서, 부갑상선 호르몬 대 랄옥시펜의 몰비가 10:1 내지 1:10인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940017456A 1993-07-22 1994-07-20 골량을 증가시키기위한 부갑상선호르몬 및 랄옥시펜 KR100306852B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9648093A 1993-07-22 1993-07-22
US08/096,480 1993-07-22

Publications (2)

Publication Number Publication Date
KR950002785A true KR950002785A (ko) 1995-02-16
KR100306852B1 KR100306852B1 (ko) 2001-11-30

Family

ID=22257534

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940017456A KR100306852B1 (ko) 1993-07-22 1994-07-20 골량을 증가시키기위한 부갑상선호르몬 및 랄옥시펜

Country Status (30)

Country Link
US (1) US5510370A (ko)
EP (1) EP0635270B1 (ko)
JP (1) JPH0769920A (ko)
KR (1) KR100306852B1 (ko)
CN (1) CN1105577C (ko)
AT (1) ATE189959T1 (ko)
AU (1) AU686628B2 (ko)
BR (1) BR9402902A (ko)
CA (1) CA2128376A1 (ko)
CY (1) CY2192B1 (ko)
CZ (1) CZ289648B6 (ko)
DE (1) DE69423146T2 (ko)
DK (1) DK0635270T3 (ko)
ES (1) ES2142380T3 (ko)
GR (1) GR3033492T3 (ko)
HK (1) HK1013800A1 (ko)
HU (1) HU219382B (ko)
IL (1) IL110350A (ko)
MY (1) MY124311A (ko)
NO (1) NO942708L (ko)
NZ (2) NZ264027A (ko)
PE (1) PE14595A1 (ko)
PH (1) PH30686A (ko)
PL (1) PL304348A1 (ko)
PT (1) PT635270E (ko)
RU (1) RU2155042C2 (ko)
SI (1) SI0635270T1 (ko)
TW (1) TW303299B (ko)
YU (1) YU49170B (ko)
ZA (1) ZA945249B (ko)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5502074A (en) * 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
KR970705397A (ko) * 1994-09-08 1997-10-09 레이셔 야코버스 코넬리스 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
IL117036A0 (en) * 1995-02-06 1996-06-18 Lilly Co Eli Methods of inhibiting effects of il-6
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
AU761274B2 (en) * 1996-01-29 2003-05-29 Schering Aktiengesellschaft Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
WO1999004808A1 (fr) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Medicaments dentaires contenant de la pth
JP2001519384A (ja) * 1997-10-14 2001-10-23 イーライ・リリー・アンド・カンパニー 骨の構築と維持のための方法
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1119251A4 (en) * 1998-10-07 2004-03-24 Univ Arkansas METHOD FOR SCREENING ON ANALOG BONE THERAPY ACTIVE SUBSTANCES THAT CONTROL APOPTOSIS AND THEIR USE
AU1525700A (en) 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
WO2002030264A2 (en) * 2000-10-10 2002-04-18 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
ATE394099T1 (de) * 2001-11-29 2008-05-15 Gtx Inc Vorbeugung und behandlung von durch androgenmangel induzierter osteoporose
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
CA2489098A1 (en) * 2002-06-13 2003-12-24 Wyeth Bazedoxifene treatment regimens
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
BRPI0506774A (pt) * 2004-01-13 2007-05-22 Wyeth Corp métodos de tratar ou inibir osteoporose ou osteopenia em um mamìfero, de tratar ou inibir cáncer de mama em um mamìfero, de inibir a recorrência do cáncer de mama em um mamìfero e de inibir cáncer de mama em uma mulher em alto risco, uso de um bazedoxifeno, produto, e, composição
MXPA06013168A (es) * 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
US7488316B2 (en) * 2005-01-25 2009-02-10 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) * 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
SI3345607T1 (sl) * 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
EP2537539B1 (en) 2007-04-13 2019-04-03 Kuros Biosurgery AG Polymeric Tissue Sealant
US8241294B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US8241363B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8876905B2 (en) * 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CA2795886A1 (en) * 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
WO2015187994A1 (en) * 2014-06-04 2015-12-10 Cedars-Sinai Medical Center Method for non surgical repair of vertebral compression fractures
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
SI0635270T1 (en) 2000-08-31
AU6757794A (en) 1995-02-02
GR3033492T3 (en) 2000-09-29
CY2192B1 (en) 2002-11-08
PH30686A (en) 1997-09-16
KR100306852B1 (ko) 2001-11-30
TW303299B (ko) 1997-04-21
CZ289648B6 (cs) 2002-03-13
BR9402902A (pt) 1995-04-11
YU46794A (sh) 1997-03-07
IL110350A0 (en) 1994-10-21
DE69423146D1 (de) 2000-04-06
NZ264027A (en) 1996-03-26
PE14595A1 (es) 1995-06-01
PT635270E (pt) 2000-07-31
US5510370A (en) 1996-04-23
PL304348A1 (en) 1995-01-23
EP0635270B1 (en) 2000-03-01
ZA945249B (en) 1996-01-18
ATE189959T1 (de) 2000-03-15
NO942708D0 (no) 1994-07-19
DK0635270T3 (da) 2000-06-05
HU219382B (en) 2001-03-28
NO942708L (no) 1995-01-23
CA2128376A1 (en) 1995-01-23
DE69423146T2 (de) 2000-09-21
ES2142380T3 (es) 2000-04-16
HU9402157D0 (en) 1994-09-28
CN1105577C (zh) 2003-04-16
EP0635270A1 (en) 1995-01-25
RU94027680A (ru) 1996-11-10
JPH0769920A (ja) 1995-03-14
YU49170B (sh) 2004-05-12
MY124311A (en) 2006-06-30
NZ280040A (en) 1997-06-24
AU686628B2 (en) 1998-02-12
HUT67945A (en) 1995-05-29
RU2155042C2 (ru) 2000-08-27
CN1105882A (zh) 1995-08-02
IL110350A (en) 2002-02-10
CZ173394A3 (en) 1995-04-12
HK1013800A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
KR920019342A (ko) 골질환 치료제
HK1003978A1 (en) Composition for the treatment of schizophrenia
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
KR930016102A (ko) 과증식 혈관 질환 치료용 조성물
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
KR890015742A (ko) 이병치료용 국소 제제
BR9809571A (pt) Composição medicinal e processo para produzì-la
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DK178188A (da) Antivirusmiddel
GR3032224T3 (en) Therapeutic agent for threatened abortion.
SE7708176L (sv) Bensamidforeningar
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
KR900017599A (ko) 종양 치료용 약학 조성물
KR900012622A (ko) 피부질환치료 조성물
SE8802040D0 (sv) New use
KR930702016A (ko) 골다공증 치료제
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR890007737A (ko) 진토작용을 하는 약제

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040714

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee